Must not have received prior EBV or LMP-specific T cells within  days of entry onto this study
Severe, active co-morbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last  months PRIOR TO registration\r\n* Transmural myocardial infarction within the last  months prior to study entry\r\n* Unstable ventricular arrhythmia within the last  months prior to study entry\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics within  days prior to study entry\r\n* Hepatic insufficiency resulting in clinical jaundice, encephalopathy and/or variceal bleed within  days prior to study entry\r\n* Bleeding within  days prior to study entry due to any cause, requiring transfusion\r\n* Thrombolytic therapy within  days prior to study entry; subcutaneous heparin is permitted\r\n* Known bleeding or clotting disorder\r\n* Uncontrolled psychotic disorder
Patients fulfilling the following criteria will be eligible for entry into this study:
Patients with ureteral obstruction must undergo stent or nephrostomy tube placement prior to study entry
Patient may have started imatinib prior to study entry but has not received more than  days of imatinib
Grade  or greater rash of any cause at time of study entry
Use of over the counter (OTC) PPIs within  months prior to study entry\r\n* Esomeprazole (Nexium)\r\n* Lansoprazole (Prevacid)\r\n* Omeprazole (Prilosec, Zegerid)
Use of orlistat or any other known FASN inhibitor within  months prior to study entry
Must not have received any biological modifier within  days of entry on to this study
At the time of study entry, blood counts performed within  weeks prior to study entry must meet the following criteria:
Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be performed within  days prior to study entry according to institutional standards for women of childbearing potential.)
Progressive cancer at the time of study entry
Use of tumor necrosis factor (TNF) alpha inhibitors within four weeks prior to study entry
Ipsilateral axillary lymph nodes must be evaluated by imaging (mammogram, ultrasound, and/or MRI) within  days prior to study entry. If suspicious or abnormal, FNA or core biopsy is recommended. Findings of these evaluations will be used to define the nodal status prior to study entry according to the following criteria:
Excisional biopsy or lumpectomy performed prior to study entry.
Baseline tumor measurements must be documented from tests within  days of study entry; other non-laboratory tests must be performed within  days of study entry
Laboratory tests required for eligibility must be completed within  days prior study entry; baseline tumor measurements must be documented from tests within  days of study entry; other non-laboratory tests must be performed within  days of study entry
Patients taking sertraline at the time of study entry will not be eligible for the study
The subject has tested positive for the Clostridium difficile toxin within  days of study entry.
Any of the following prior therapies:\r\n* Chemotherapy =<  weeks prior to study entry\r\n* Immunotherapy =<  weeks prior to study entry\r\n* Biologic therapy =<  weeks prior to study entry\r\n* Extensive abdominal surgery if it includes enterotomy(ies) =<  weeks prior to study entry; (NOTE: this criterion does not apply to placement of the peritoneal Port-A-Cath or lysis of adhesions at the time of study entry)\r\n* Any viral or gene therapy prior to study entry
Initial diagnosis of metastatic disease must have occurred ? weeks prior to entry in the study.
Hepatic inclusion within  weeks of entry
Normal mammogram of unaffected breast within  months prior to study entry
No other therapy (i.e. chemotherapy, interferon) for  weeks prior to study entry, or cladribine for  months prior to study entry
Patients on -alpha reductase inhibitors such as finasteride or dutasteride must stop medication at least  days prior to study entry.
Patients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study
Has distant metastatic disease on imaging or staging laparoscopy at the time of study entry
Patients who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must have been adequately treated for at least  weeks before study entry; subjects with bacteremia must have documented negative blood cultures prior to study entry
Imaging evaluations necessary to establish eligibility for study entry must be done within three () weeks prior to registration
All other evaluations necessary to establish eligibility for study entry must be done within two () weeks prior to registration
Subject who have received ferumoxytol within  weeks of study entry
Patients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study
Subject who have received ferumoxytol within  weeks of study entry
History of acute urinary retention within  months of study entry;
The investigator must document that he/she believes the subject would not benefit from additional BCG treatment at the time of study entry
Chemotherapy must not have been received within  weeks of entry onto this study
Previous intravesical therapy within  months of study entry.
Symptomatic brain metastases or meningeal tumors or other uncontrolled metastases in the central nervous system (CNS) unless the patient\r\n* Is >  months from definitive therapy,\r\n* Has a negative imaging study within  weeks before study entry (informed consent form [ICF] signature for full study) and\r\n* Is clinically stable with respect to the tumor at the time of study entry
Hyperleukocytosis (leukocytes ? x /L) at study entry. These patients may be treated with hydroxyurea according to routine practice, and enroll in the study when the leukocyte count falls below  x /L.
Appropriate stage for protocol entry including no clinical evidence for distant metastases based upon the following minimum diagnostic workup:\r\n* History/physical examination, documentation of weight and Zubrod performance status - within  days prior to study entry\r\n* Right and left mammography within  days of diagnostic biopsy establishing diagnosis
The etiology of abnormal bilirubin and transaminase levels should be evaluated prior to study entry
Radiographic or cytologic evidence of leptomeningeal or multifocal disease at any time prior to study entry
Participants must not have an invasive infection at time of protocol entry
No abnormalities on pre-entry electrocardiogram, obtained within  days prior to being registered on study
Patients who are receiving treatment with medications that cannot be discontinued prior to study entry and that are considered to be any of the following:
Subjects with bacteremia must have documented negative blood cultures prior to study entry
Fully resected disease at study entry (residual CIS acceptable)
Platelets >  x ^/L within  days of study entry
We will allow XRT prior to study entry to other sites, with no washout period, allowed prior to study entry as long as at least one measurable sites of disease is kept unirradiated
Biologic therapy (anti-neoplastic)\r\n* Must not have received oral tyrosine kinase inhibitors (other than dasatinib) or other similar agents within  weeks of the study entry and all toxicities must have resolved to < grade  prior to enrollment\r\n* Must not have received bevacizumab or other monoclonal antibody therapy within  weeks of study the entry
Use of zidovudine as part of the HAART regimen (a drug substitution for zidovudine at the time of study entry is allowed)
At the time of study entry, blood counts performed within  weeks prior to study entry must meet the following criteria:
Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be performed within  days prior to study entry according to institutional standards for women of childbearing potential.)
Patients receiving erythropoietin (darbepoetin, epoetin alfa) must be on a stable dose and with stable transfusion requirement or hemoglobin level during the  weeks prior to study entry
Tumor not suitable for resection at the time of study entry; (transplant eligible patients are allowed)
Histologically confirmed AML by hematopathology review performed within four weeks prior to study entry
Allogeneic or autologous transplant for AML with infusion of stem cells within  days of study entry or on active immunosuppressive therapy for (GVHD) within  weeks before study entry
Patients who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least  weeks before study entry; patients with bacteremia must have documented negative blood cultures prior to study entry
Skin biopsy performed at least  days and no longer than  weeks from the time of initial entry into the study
Participants must not have an invasive infection at time of protocol entry
All patients must undergo pre-treatment evaluation of tumor extent prior to study entry through imaging studies and clinical examinations, including computed tomography (CT) and/or magnetic resonance imaging (MRI) of skull base, brain and neck within  days prior to study entry; physical examination +/- nasal endoscopy within  days prior to study entry; and CT of the chest within  days prior to study entry
Must not have received any biological modifier within  days of entry on to this study
No other therapy (i.e. chemotherapy, interferon) for  weeks prior to study entry, or cladribine for  months prior to study entry, unless progressive disease more than  months after cladribine is documented
Patients receiving finasteride (Proscar) or dutasteride (Avodart) or men who have received either agent within  days of entry are ineligible
Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be performed within  days prior to study entry according to institutional standards for women of childbearing potential.)
Did not receive any investigational treatment for at least  days prior to study entry
Completed autologous BMT (if received) at least  months prior to study entry; completed allogeneic BMT (if received); at least  months prior to study entry
Consultations: all patients should be evaluated by a surgeon prior to study entry
Women may have been taking tamoxifen or raloxifene as a preventive agent prior to study entry but must have discontinued the drug for at least  days prior to study enrollment
Subjects with bacteremia must have documented negative blood cultures prior to study entry
Patients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study
Patients with ureteral obstruction (i.e., hydronephrosis identified on CT imaging) must undergo stent or nephrostomy tube placement prior to study entry
Diabetic patients requiring insulin for glucose control at the time of study entry
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Myelosuppressive chemotherapy: Must not have received within  weeks of entry onto this study ( weeks if prior nitrosourea)\r\n* Biologic (anti-neoplastic agent): At least  days since the completion of therapy with a biologic agent; at least  weeks for biologic agents with a long half life, such as antibodies\r\n* External beam radiation therapy (XRT): Must not have received craniospinal radiotherapy within  weeks prior to study entry; the tumor designated as measurable for protocol purposes must not have received radiation within  weeks prior to study entry); focal radiation to areas of symptomatic metastatic disease must not be given within  days of study entry\r\n* Stem cell transplant (SCT): For autologous SCT, >=  months must have elapsed prior to study entry\r\n* Study specific limitations on prior therapy:\r\n** Patients must not have previously received bevacizumab, irinotecan, temozolomide or other anti-vascular endothelial growth factor (VEGF) inhibitor\r\n** Patients must not be taking enzyme-inducing antiepileptic medicines within  week of study entry
Use of zidovudine or cobicistat as part of the HAART regimen (a drug substitution at the time of study entry is allowed)
Any acute, inter-current infection that may interfere with planned protocol treatment; participants with mycobacterium avium will not be excluded from study entry; chronic therapy with potentially myelosuppressive agents is allowed provided that entry hematologic criteria are met
Off all myelofibrosis (MF)-directed therapy including investigational agents for at least  weeks prior to study enrollment and recovered from all toxicities; patient who has been on stable dose of ruxolitinib and has received ruxolitinib =<  months prior to the study entry will be considered potentially eligible for the study with the caveat that there is no evidence of loss of response (>  cm increase in spleen size from the nadir)
Diagnosed less than  years prior to entry on trial
previous intravesical BCG therapy, which can be given at least  weeks before the diagnostic biopsy required for entry into the study
The presence of any of the following will exclude a subject from enrollment into the Induction and Maintenance parts of the study (except if specified at study entry only):
Proliferative disease (WBC >  x  /L) (confirmed at time of study entry prior to first dose)
Fludarabine or Campath within  months prior to study entry
Patients must not have prior history of desquamating rash from thalidomide at time of study entry
History of ischemic cardiac disease that has occurred within  months prior to study entry.
Hgb <  g/L, have received ?  units PRBC in the  weeks prior to study entry, and be intolerant of or had inadequate response to ruxolitinib;
Patients must also have documented evidence of PD during or within  days (measured from the end of the last cycle) of completing treatment with the last anti-myeloma drug regimen used just prior to study entry (refractory disease).
have had unprotected sexual intercourse within  days before study entry,
Normal carcinoembryonic antigen (CEA) prior to study entry
Patients who have received any treatment with ibrutinib prior to study entry
Chemotherapy or other investigational anticancer therapeutic drugs in the two weeks prior to study entry; in the event of rapidly proliferative disease, however, the use of hydroxyurea is permitted up to  hours before study entry in core
Appropriate stage for protocol entry, including no clinical evidence for distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination, including breast exam and documentation of weight and Karnofsky performance status of -% at study entry
Patients who have received any treatment with SGN- prior to study entry
Patients must not have received any prior chemotherapy, radiation therapy, biologic therapy, or bone marrow transplant; surgery and dexamethasone are permitted prior to study entry; in patients who require anticonvulsants prior to study entry, it is permissible to start VPA, but trough VPA concentration must be repeated within  hours of study entry
Patients with abnormality of the tibial metaphyseal plate on plain x-ray prior to study entry are not eligible
Concurrent treatment with estrogens or progestins; patients must stop these drugs at least two weeks prior to study entry
Previous local therapy (e.g., chemoembolization or bland embolization) is allowed if completed >  weeks prior to study entry; for such patients, there must be either progression of measurable disease documented within the treatment field, or measurable progressive disease outside the treatment field prior to study entry
Previous chemotherapy and/or investigational agents are allowed if completed >  weeks prior to study entry (>  weeks if last regimen contained bis-chloroethyl nitrosourea [BCNU] or mitomycin C); for patients who received systemic therapy prior to study entry, there must be documented progression of measurable disease since receiving systemic therapy prior to study entry
Patients who have completed sipuleucel-T (Provenge ) treatment within  days of study entry.
Patient has: random glucose >  mg/dl or is taking an oral hypoglycemic agent or insulin at the time of study entry
Diabetics on insulin or antihyperglycemics must be on a stable dose (i.e., no titrations within the last  weeks) at the time of study entry
Diabetics on insulin or antihyperglycemics must be on a stable dose (i.e., no titrations within the last  weeks) at the time of study entry
Receiving baseline systemic glucocorticoid therapy (at stable dose) for cGVHD at study entry.
Patients will be registered on study based on the local exam under anesthesia (EUA) done for diagnostic purposes prior to study entry; the EUA done at study entry should be done within  days prior to study entry
Patient should have a normalized or normal uric acid level prior to study entry
History of arterial or embolic events (within  months prior to study entry)
Laboratory tests required for eligibility must be completed within  days prior study entry; baseline tumor measurements and ECHO or MUGA must be documented from tests completed within  days of study entry; other non-laboratory tests must be performed within  days of study entry
Patients with the following within the last  months prior to registration must be evaluated by a cardiologist and/or neurologist prior to entry into the study
Participants must not have a concurrent malignancy unless it can be adequately treated by non-chemotherapeutic intervention; participants may have a history of prior malignancy, provided that he/she has not had any chemotherapy within  days of study entry AND that life expectancy exceeds  years at the time of study entry
Patients treated with interferon or other anti-HCV therapy within  months prior to study entry
Subjects with bacteremia must have documented negative blood cultures prior to study entry
Treatment within the last  days with a drug that has not received regulatory approval for any indication at the time of study entry
Participants must have baseline echocardiogram and pulmonary function tests within  months prior to study entry
Vaginal bleeding of unknown etiology within  months of study entry
Patient has been treated with nelfinavir within  months of entry into this trial
Have received treatment within the last  days prior to study entry with any drug that has not received regulatory approval for an indication at the time of study entry
Patient has at least  years of nilotinib treatment prior to study entry.
Patients must be off hydroxyurea (HU) or erythropoietin (EPO) treatment for at least three months prior to entry onto the study
Oral retinoid therapy for any indication within  weeks of study entry
Prior radiation therapy (RT) within  months of study entry
Note: laboratory tests required for eligibility must be completed within  weeks prior to study entry; baseline measurements in the CNS must be documented from tests within  days of study entry; other non-laboratory tests must be performed as indicated
For bevacizumab-naive patients (groups  and ) a minimum of  months must have elapsed since completion of radiation therapy for study entry, and there is no minimum time since completion of last chemotherapy; for bevacizumab-exposed patients (groups  and ) no minimum time since completion of last radiation therapy, biologic agents, or chemotherapy will be required for study entry
Systemic chemotherapy within  weeks prior to study entry (signing consent form)
Radiation therapy for splenomegaly within  months prior to study entry
Previous treatment for APL, except tretinoin, which may be given for up to  days prior to study entry
Recovered from side effects that might interfere with the protocol therapy and:\r\n* >=  weeks must have elapsed from last radiation treatment to time of study entry\r\n* >=  weeks must have elapsed from the last chemotherapy administration to time of study entry\r\n* >=  weeks from the last immunotherapeutic agent administered to time of study entry
Study participant must use birth control measure prior to study entry (during screening), during study participation, and for  weeks after bevacizumab is discontinued
Any chemotherapy and/or radiation therapy received =<  months of study entry and any immunotherapy received =<  months of study entry (with the execption of Bacillus Calmette-Guerin [BCG] treatment)
Imaging evaluations necessary to establish eligibility for study entry must be done within three () weeks prior to registration; all other evaluations necessary to establish eligibility for study entry must be done within two () weeks prior to registration; in the event that the patients condition deteriorates (performance score < ) within  hours prior to the injection the patient is no longer eligible to receive HSV injection
Patients must have measurable disease as defined by palpable lesion with both diameters >=  cm measurable with caliper and/or a positive mammogram or ultrasound with at least one dimension >=  cm; bilateral mammogram and clip placement is required for study entry; baseline measurements of the indicator lesions must be recorded on the Patient Registration Form; to be valid for baseline, the measurements must have been made within the  days if palpable; if not palpable, a mammogram or magnetic resonance imaging (MRI) must be done within  days; if palpable, a mammogram or MRI must be done within  months prior to study entry; if clinically indicated, x-rays and scans must be done within  days of study entry
Patient must be able to be treated with remestemcel-L within  days of study entry.
Congenital TTP (known at the time of study entry).
Individuals must have been on a stable dose of ruxolitinib for at least  weeks prior to study entry
Chemotherapy or other investigational anticancer therapeutic drugs within  week prior to study entry unless AEs have resolved and there is no interference with the assessment of efficacy or safety; in the event of rapidly proliferative disease, however, the use of hydroxyurea is permitted up to  hours before study entry. Patients with prior bone marrow or stem cell transplant, considered for inclusion, should be discussed with the medical monitor first.
Patients may receive hydroxyurea, low-dose cytarabine and/or glucocorticoids to control peripheral blood leukemic cell counts at study entry
Diagnostic examination under anesthesia (EUA) must be performed within  days prior to study entry
Symptomatic metastatic brain or meningeal tumors unless the patient is >  months from definitive therapy, has a negative imaging study within  weeks of study entry and is clinically stable with respect to the tumor at the time of study entry.
Received bisphosphonates (e.g., etidronate, clodronate, tiludronate, pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate, zoledronate) within  weeks prior to study entry
Must have known MGMT methylation and IDH mutation status to be screened for study entry.
Donor must not have an active infection at the time of study entry.
Patients with cirrhosis must have had esophagogastric endoscopy within the previous  months prior to study entry for the assessment of varices; if the patient has not had this done they must be willing to undergo this procedure prior to study entry
Because the effects of ofatumumab on fetuses and nursing infants are not known, the following are ineligible for study entry:
Measurable disease at the time of study entry
Patients must have measurable disease as defined by palpable lesion with both diameters >=  cm measurable with caliper and/or a positive mammogram or ultrasound with at least one dimension >=  cm; bilateral mammogram and clip placement is required for study entry; baseline measurements of the indicator lesions must be recorded on the patient registration form; to be valid for baseline, the measurements must have been made within the  days if palpable; if not palpable, a mammogram or magnetic resonance imaging (MRI) must be done within  days; if palpable, a mammogram or MRI must be done within  months prior to study entry; if clinically indicated, x-rays and scans must be done within  days of study entry
The participant has metastatic disease at the time of study entry
Chemotherapy or other investigational anticancer therapeutic drugs within  week prior to study entry. AEs from prior therapy must have resolved or stabilized so that there is no interference with the assessment of efficacy or safety; in the event of rapidly proliferative disease, however, the use of hydroxyurea is permitted up to  hours before study entry. Patients with prior bone marrow or stem cell transplant, considered for inclusion, should be discussed with the medical monitor first.
Fludarabine or Campath within  months prior to study entry
Has distant metastatic disease on imaging or staging laparoscopy at the time of study entry
Prior biologic or immunologic therapy =<  weeks prior to study entry
Patients who have received any treatment of ponatinib prior to study entry
Uncontrolled angina within  months prior to study entry;
In remission at time of study entry, may be receiving chemoprevention
Presence of do not resuscitate (DNR)/do not intubate (DNI) orders at study entry
Use of finasteride or dutasteride within  weeks or  months, respectively, of study entry
There is evidence of the disease at the time of entry into the trial
If patients are on opioids for the treatment of cancer pain, they must have had no dose changes (> %) for at least  hours prior to study entry; change in opioid dose after study entry is allowed
Patients may have started consolidative chest irradiation by the time of study entry
Time from completion of cancer treatment to study entry: >=  years
Presence of hot flashes for >  days prior to study entry
If patients are on opioids for the treatment of cancer pain, they must have had no major dose change (> %) for at least  hours prior to study entry; change in opioid dose after study entry is allowed
Non-randomized pilot cohort:\r\n* Concurrent chemotherapy (initiated within  months of study entry) or planned chemotherapy within  months of study entry
Vaginal dryness or dyspareunia must be present for at least two months prior to study entry
The patient has a clinical negative node status at the time of study entry (i.e. T-, M, tumor staging criteria)
Use of allopurinol within  hours of the study entry
Subjects who are taking drugs known to interact with posaconazole and that may lead to life-threatening side effects (terfenadine, cisapride, and ebastine at entry or within  hours before entry, or astemizole at entry or within  days before entry)
Subjects who are taking drugs known to lower the serum concentration/efficacy of posaconazole: cimetidine, rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, and isoniazid at entry or within  hours before entry
Presence of hot flashes for >= month prior to study entry
Baseline mammogram performed within  days prior to study entry, done on a digital mammography machine, that are reported as normal or benign.
Participants must be willing to abstain from drinking green tea or taking supplements containing green tea or green tea compounds, for the duration of the investigation and for  days prior to study entry\r\n* (Please note that patients with a treated TN or TN squamous carcinoma and who do not have a pre-malignant measurable lesion at the time of study entry will not be subjected to a biopsy but will have cytobrush samples taken as specified in the protocol)
Completion of first-line radiation at least  months prior to study entry.
History of DHA supplementation >  mg/day in the month preceding study entry
Patients on aromatase inhibitors other than letrozole at study entry.
The patient has a clinical negative node status at the time of study entry (i.e., Tis-, N, M)
Subject who have received ferumoxytol within  weeks of study entry
Subject who have received ferumoxytol within  weeks of study entry
Subject who have received ferumoxytol within  weeks of study entry
The patient must agree at the time of study entry to undergo clinically indicated biopsy(ies) or -month period of follow-up, as needed, to resolve the etiology of their IPN(s) or lung mass(es)
Patients having undergone prior hysterectomy will be eligible provided that they meet the other requirements for entry into this study
After entry into the study, participants agree to be followed for up to  weeks after the final infusion of ferumoxytol
Patient must not have received craniospinal radiotherapy or involved field radiotherapy to the local tumor (and/or tumor designated as measurable for protocol purposes) =<  weeks prior to study entry; focal radiation to areas of symptomatic metastatic disease must not be given within  days of study entry
Replacement hormone therapy initiated before study entry is permitted
Replacement hormone therapy initiated before study entry is permitted
N and M at the time of study entry.
Men and women diagnosed with CP-CML, on treatment with dasatinib for a minimum of  years at the time of enrollment and in dasatinib-induced complete molecular remission ongoing for at least  year prior to study entry.
Patients with treated brain metastases are eligible if they are >  weeks from therapy completion (including radiation and/or surgery), are clinically stable at the time of study entry and are not receiving corticosteroid therapy at the time of study entry
has been diagnosed less than  months before study entry and/or
